WO2007011693A3 - Compositions of placentally-derived stem cells for the treatment of cancer - Google Patents

Compositions of placentally-derived stem cells for the treatment of cancer Download PDF

Info

Publication number
WO2007011693A3
WO2007011693A3 PCT/US2006/027305 US2006027305W WO2007011693A3 WO 2007011693 A3 WO2007011693 A3 WO 2007011693A3 US 2006027305 W US2006027305 W US 2006027305W WO 2007011693 A3 WO2007011693 A3 WO 2007011693A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
stem cells
compositions
placentally
treatment
Prior art date
Application number
PCT/US2006/027305
Other languages
French (fr)
Other versions
WO2007011693A2 (en
Inventor
Thomas E Ichim
Original Assignee
Medistem Lab Inc
Thomas E Ichim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medistem Lab Inc, Thomas E Ichim filed Critical Medistem Lab Inc
Publication of WO2007011693A2 publication Critical patent/WO2007011693A2/en
Publication of WO2007011693A3 publication Critical patent/WO2007011693A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are preparations of placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a 'guided differentiation' program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.
PCT/US2006/027305 2005-07-14 2006-07-12 Compositions of placentally-derived stem cells for the treatment of cancer WO2007011693A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69957905P 2005-07-14 2005-07-14
US60/699,579 2005-07-14

Publications (2)

Publication Number Publication Date
WO2007011693A2 WO2007011693A2 (en) 2007-01-25
WO2007011693A3 true WO2007011693A3 (en) 2007-05-10

Family

ID=37193805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/027305 WO2007011693A2 (en) 2005-07-14 2006-07-12 Compositions of placentally-derived stem cells for the treatment of cancer

Country Status (2)

Country Link
US (4) US20070041954A1 (en)
WO (1) WO2007011693A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8926964B2 (en) 2010-07-13 2015-01-06 Anthrogenesis Corporation Methods of generating natural killer cells
US9216200B2 (en) 2007-09-28 2015-12-22 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046373A1 (en) * 2000-12-06 2002-06-13 Hariri Robert J Method of collecting placental stem cells
EP1571910A4 (en) * 2002-11-26 2009-10-28 Anthrogenesis Corp Cytotherapeutics, cytotherapeutic units and methods for treatments using them
NZ542127A (en) * 2003-02-13 2008-04-30 Anthrogenesis Corp Use of umbilical cord blood to treat individuals having a disease, disorder or condition
CN101966183A (en) * 2003-12-02 2011-02-09 细胞基因公司 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
AU2006294581B2 (en) 2005-09-27 2011-11-03 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
WO2007047468A2 (en) 2005-10-13 2007-04-26 Anthrogenesis Corporation Immunomodulation using placental stem cells
EP1965812A4 (en) * 2005-11-08 2010-02-24 Georgia Tech Res Inst Acellularized biomaterial from embryonic stem cells
NZ595786A (en) * 2005-12-29 2013-05-31 Anthrogenesis Corp Placental stem cell populations
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
WO2008051568A2 (en) * 2006-10-23 2008-05-02 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2630959A1 (en) * 2007-02-12 2013-08-28 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
KR101039235B1 (en) 2007-08-29 2011-06-07 메디포스트(주) Composition for the diagnosis, prevention or treatment of diseases related to cells expressing IL-8 or GRO-?, comprising UCB-MSCs
WO2009042201A1 (en) * 2007-09-26 2009-04-02 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
WO2009061447A2 (en) * 2007-11-07 2009-05-14 Anthrogenesis Corporation Treatment of premature birth complications
PL2281030T3 (en) * 2008-05-19 2017-07-31 Dcprime B.V. Method for inducing and accelerating cells
CA2734236C (en) * 2008-08-20 2020-08-25 Anthrogenesis Corporation Improved cell composition and methods of making the same
NZ591293A (en) * 2008-08-22 2012-10-26 Anthrogenesis Corp Methods and compositions for treatment of bone defects with osteogenic placental adherent cells (OPACs)
NZ602455A (en) * 2008-11-19 2014-03-28 Anthrogenesis Corp Amnion derived adherent cells
BRPI0921999B8 (en) * 2008-11-21 2021-05-25 Anthrogenesis Corp use of a therapeutically effective amount of placental stem cells
PT2411506T (en) * 2009-03-25 2019-03-19 Celularity Inc Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
CA2787992A1 (en) * 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
EP3345998A1 (en) 2010-02-18 2018-07-11 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
KR20200047797A (en) 2010-04-07 2020-05-07 안트로제네시스 코포레이션 Angiogenesis using placental stem cells
CN102933221A (en) 2010-04-08 2013-02-13 人类起源公司 Treatment of sarcoidosis using placental stem cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
ES2707579T3 (en) 2011-06-01 2019-04-04 Celularity Inc Pain treatment using placental cytoblast
ES2822301T3 (en) 2011-06-10 2021-04-30 Tissuetech Inc Fetal Support Tissue Processing Methods
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US9821026B2 (en) * 2012-06-28 2017-11-21 Instituto De Medicina Molecular Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
TW201603818A (en) 2014-06-03 2016-02-01 組織科技股份有限公司 Compositions and methods
DE102014013229A1 (en) * 2014-09-05 2016-03-10 Fresenius Medical Care Deutschland Gmbh Apparatus for performing a tidal peritoneal dialysis treatment
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CN107847526A (en) 2015-05-20 2018-03-27 组织技术公司 For preventing the propagation of epithelial cell and the composition and method of the conversion of epithelium mesenchyma
TW201733600A (en) 2016-01-29 2017-10-01 帝聖工業公司 Fetal support tissue products and methods of use
CA3012741A1 (en) * 2016-02-18 2017-08-24 Pluristem Ltd. Methods and compositions for treating cancer and neoplasms
CN106324173B (en) * 2016-08-23 2018-05-25 国家烟草质量监督检验中心 A kind of measure screening technique of the laryngocarcinoma serum difference metabolin based on reverse-phase chromatography flight time mass spectrum
CN109908177A (en) * 2017-12-12 2019-06-21 北京弘润天源基因生物技术有限公司 A kind of preparation method of the stem cell secretion factor Essence for wound healing
WO2019118762A1 (en) * 2017-12-14 2019-06-20 Iti Technologies, Inc. Chemical process and product
CN108753876B (en) * 2018-05-25 2022-06-14 华子昂 Method for enhancing expression of stem cell surface receptor CXCR4 by using sheep placenta extract
CN111476321B (en) * 2020-05-18 2022-05-17 哈尔滨工程大学 Air flyer identification method based on feature weighting Bayes optimization algorithm
CN113679741B (en) * 2021-09-13 2023-09-19 北京大学第一医院 Application of human amniotic epithelial stem cells in preparation of medicines for treating cisplatin-induced acute kidney injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028660A1 (en) * 2002-05-30 2004-02-12 Anthrogenesis Corporation Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5221570B2 (en) * 1973-08-30 1977-06-11
EP0029893B1 (en) * 1979-11-02 1987-05-20 Karl Prof. Dr. Theurer Process for concentration of tumor-inhibiting substances
HU226419B1 (en) * 1996-03-11 2008-12-29 Aerovance Human bikunin
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US7204982B2 (en) * 2002-07-02 2007-04-17 The Regents Of The University Of California Compositions and methods for treatment and detection of multiple cancers
TWI310686B (en) * 2002-10-18 2009-06-11 You Ru Qian
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028660A1 (en) * 2002-05-30 2004-02-12 Anthrogenesis Corporation Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANGELUCCI C ET AL: "The growth of malignant and nonmalignant human cells is modulated by a human placental extract.", ANTICANCER RESEARCH. 1999 JAN-FEB, vol. 19, no. 1A, January 1999 (1999-01-01), pages 429 - 436, XP009074647, ISSN: 0250-7005 *
COHEN YOSSI ET AL: "Umbilical cord blood transplantation--how, when and for whom?", BLOOD REVIEWS. SEP 2004, vol. 18, no. 3, September 2004 (2004-09-01), pages 167 - 179, XP002406814, ISSN: 0268-960X *
KIM DONG HOON ET AL: "Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.", JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY. 31 JAN 2003, vol. 36, no. 1, 31 January 2003 (2003-01-31), pages 110 - 119, XP002406812, ISSN: 1225-8687 *
KLEIN J L ET AL: "Growth of only highly tumorigenic cell lines is inhibited by EAP, a human placental fraction.", CANCER LETTERS. 15 JUN 1993, vol. 70, no. 1-2, 15 June 1993 (1993-06-15), pages 91 - 99, XP002406809, ISSN: 0304-3835 *
KLEIN J L ET AL: "Growth suppression of transformed cells by a human placental extract not related to transforming growth factor beta.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 1991, vol. 117, no. 3, 1991, pages 192 - 196, XP009074648, ISSN: 0171-5216 *
MCLAUGHLIN FIONA ET AL: "Histone deacetylase inhibitors open new doors in cancer therapy.", BIOCHEMICAL PHARMACOLOGY. 15 SEP 2004, vol. 68, no. 6, 15 September 2004 (2004-09-15), pages 1139 - 1144, XP002406811, ISSN: 0006-2952 *
SU ZHONG-JING ET AL: "Effects of dendritic cells from cord blood CD34+ cells on human hepatocarcinoma cell line BEL-7402 in vitro and in SCID mice.", WORLD JOURNAL OF GASTROENTEROLOGY : WJG. 28 APR 2005, vol. 11, no. 16, 28 April 2005 (2005-04-28), pages 2502 - 2507, XP002406813, ISSN: 1007-9327 *
ZHONG ZHAOHUI ET AL: "Induction of antitumor immunity through xenoplacental immunization.", JOURNAL OF TRANSLATIONAL MEDICINE [ELECTRONIC RESOURCE]. 2006, vol. 4, 2006, pages 22, XP002406815, ISSN: 1479-5876 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216200B2 (en) 2007-09-28 2015-12-22 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8926964B2 (en) 2010-07-13 2015-01-06 Anthrogenesis Corporation Methods of generating natural killer cells
US9464274B2 (en) 2010-07-13 2016-10-11 Anthrogenesis Corporation Methods of generating natural killer cells

Also Published As

Publication number Publication date
US20130156847A1 (en) 2013-06-20
US20170027993A1 (en) 2017-02-02
US9433646B2 (en) 2016-09-06
US20070041954A1 (en) 2007-02-22
WO2007011693A2 (en) 2007-01-25
US20110070313A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
WO2007011693A3 (en) Compositions of placentally-derived stem cells for the treatment of cancer
WO2007011962A3 (en) Treatment of cancer
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
ATE556706T1 (en) FAT ALCOHOL-DRUG CONJUGATES
WO2002069907A3 (en) Anti-neovasculature preparations for cancer
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2006083971A3 (en) Dr5 antibodies and uses thereof
WO2003083041A3 (en) Cripto-specific antibodies
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
HK1096392A1 (en) Substituted heterocycles
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06787242

Country of ref document: EP

Kind code of ref document: A2